SIBTECH, INC.

Address

115A Commerce Drive
Brookfield, CT, 06804-3400

Information

DUNS: 966566465
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. IGF OT IGF SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

    Amount: $299,999.00

    Not Available

    SBIRPhase I2015Department of Health and Human Services
  2. Targeted drug delivery to tumor microenvironment

    Amount: $224,833.00

    DESCRIPTION provided by applicant The goal of this project is to test the feasibility of targeted delivery of andquot re programmingandquot liposomal drugs to tumor associated macrophages TAMs ...

    SBIRPhase I2015Department of Health and Human Services
  3. Clinical development of 18F PET tracer for imaging VEGF receptors

    Amount: $1,473,010.00

    DESCRIPTION provided by applicant The overall goal of this collaborative Fast Track project is clinical development of a novel F PET tracer for molecular imaging of receptors for vascular endothe ...

    SBIRPhase II2015Department of Health and Human Services
  4. Clinical development of 18F PET tracer for imaging VEGF receptors

    Amount: $222,920.00

    The overall goal of this collaborative Fast-Track project is clinical development of a novel 18F PET tracer for molecular imaging of receptors for vascular endothelial growth factor (VEGFR). This rece ...

    SBIRPhase I2014Department of Health and Human Services
  5. SBIR TOPIC 85 PHASE I, DEVELOPMENT OF MOLECULAR IMAGING AGENTS AND METHODS TO DETECT HIGH RISK ATHEROSCLEROTIC PLAQUE 9/8/2014- 9/7/2015

    Amount: $224,944.00

    Not Available

    SBIRPhase I2014Department of Health and Human Services
  6. Targeted photoacoustic imaging of VEGF receptors in angiogenic vasculature

    Amount: $286,918.00

    DESCRIPTION (provided by applicant): We propose to develop a contrast agent for photoacoustic imaging targeted to the receptors of vascular endothelial growth factor (VEGFR), so it can be accumulated ...

    SBIRPhase I2011Department of Health and Human Services
  7. Targeted delivery of Lu-177 to tumor vasculature

    Amount: $1,791,385.00

    DESCRIPTION (provided by applicant): Currently available anti-angiogenic drugs inhibit VEGF/VEGFR signaling, which leads to transient vascular regression followed by rebound of drug-resistant vasculat ...

    SBIRPhase II2011Department of Health and Human Services
  8. Targeted Delivery of Cardioprotective Drugs

    Amount: $385,462.00

    DESCRIPTION (provided by applicant): Myocardial infarction is a disabling disease, with infarct size being a major determinant of mortality. To limit infarct size and improve functional recovery, the ...

    SBIRPhase I2010Department of Health and Human Services
  9. Targeted delivery of Lu-177 to tumor vasculature

    Amount: $286,382.00

    DESCRIPTION (provided by applicant): Our goal is to develop a targeted anti-cancer 177Lu radiotherapeutic agent that localizes to a tumor via receptor- mediated uptake by endothelial cells in the ...

    SBIRPhase I2009Department of Health and Human Services
  10. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer

    Amount: $245,842.00

    DESCRIPTION (provided by applicant): Drug-resistant breast cancer cells are the main cause of recurrent disease. One mechanism of cancer cell survival and drug resistance is mobilization of GRP78/BiP, ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government